Abbott suspends Indian physician ‘brand reminder’ plan amid growing industry scrutiny
This article was originally published in Scrip
Executive Summary
Abbott's decision to review the provision of free gifts to physicians in India has raised speculation that the company may be acting out of caution against a backdrop of growing scrutiny in the country and internationally against such inducements, which experts suggest more firms may be less inclined to pursue in future.
You may also be interested in...
Abbott’s Medical Camps In India: Genuine Effort or Proxy Sales Plan?
US multinational Abbott is under fire in India for allegedly using medical “camps” and a questionable “survey” approach to bolster prescriptions for its diabetic neuropathy drug, Surbex Star. Abbott has strongly denied any wrong-doing but some experts suggest it’s probably tough to delink the rub-off such activities could have on brand building.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet